- JP-listed companies
- Cash flow
【JP:4597】Cash flow
Market cap
¥7B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | - | - | - | - | 153 | 475 | 496 | 495 | 534 | 500 | 195 | 37 |
| Cash from operations | -632 | -700 | -465 | -911 | -2,323 | -828 | -2,789 | -2,473 | -2,074 | -359 | -1,033 | -847 |
| Capital expenditures | - | - | - | - | -52 | -2 | -10 | -2 | - | - | -1 | - |
| Cash from investing | -149 | -633 | -558 | -537 | -256 | -735 | -171 | -164 | -418 | - | - | -81 |
| Repurchases of common stock | - | - | - | - | -48 | -22 | - | - | - | - | - | - |
| Cash from financing | 836 | 2,934 | -34 | 3,782 | 3,260 | 1,641 | 1,829 | 361 | 2,571 | 275 | 1,180 | 1,425 |
| Free cash flow | - | - | - | - | ||||||||
| FCF margin (%) | - | - | - | - |